Navigation Links
Wound Management Technologies Exhibits at Premier International Diabetic Foot Conference DFCon 09
Date:3/20/2009

-- Accepted Abstract on CellerateRx Conducted by Dr. Matt Regulski --

FORT WORTH, Texas, March 20 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today that it is exhibiting at DFCon 09 on March 19-21, 2009 at the Renaissance Hollywood Hotel in Los Angeles, California. DFCon is considered the premier international multidisciplinary diabetic foot conference that attracts attendees from more than 50 foreign countries and all 50 U.S. states.

One of the DFCon 09's accepted abstracts this year is Activated Collagen: An Evidence Based Study (Interim Data) in Human Leg Ulcers. This abstract features Wound Care Innovations' advanced wound care collagen gel CellerateRx(R) and was conducted by Dr. Matt Regulski, Director of Wound Care Center of Ocean County, NJ. Dr. Regulski graduated Summa Cum Laude from Temple University. He is Board-certified in wound care, an associate of the American College of Foot and Ankle Surgeons (ACFAS) and a partner of the Ocean County Foot and Ankle Surgery Association. He has published several wound care papers and is a frequent speaker at medical conferences.

Dr. Regulski commented, "The initial data shows that CellerateRx treated wounds were healed by six (6) weeks and the control wounds were approximately 60% healed at fourteen (14) weeks," said Dr. Matt Regulski. "I was impressed by the speed and efficacy of CellerateRx. Diabetic ulcers remain one of the biggest problems and challenges that we face in healthcare today, both in terms of economic expenditures and patient welfare. Most amputations begin with an ulcer, so having a product that can help manage these wounds more effectively will save limbs and resources." A copy of the abstract is available online at www.Celleraterx.com.

"Dr. Regulski is one of the nation's leading specialists in diabetic wound care and limb salvage, and reconstructive surgery. We are honored to have him conducting evidence-based studies using our advanced wound care collagen product," stated Cathy Bradshaw, president of Wound Care Innovations. "CellerateRx(R) is a one of a kind, patented collagen product that comes in a powder and a gel. It is FDA cleared for use for all acute and chronic wounds, except 3rd degree burns. The results from independent studies such as Dr. Regulski's, in addition to positive feedback on CellerateRx from clinicians all over the world, indicate CellerateRx has strong potential to serve the global diabetic ulcer marketplace."

About DFCon 09

DFCon is sponsored Providence Saint Joseph Medical Center and the Providence Diabetic Foot Center in cooperation with the International Conference Management, Inc. The program is designed for the wide spectrum of generalists and specialists who diagnose and manage the diabetic foot, delving into diagnostics and interventional strategies for diabetic foot ulcers and amputation prevention. Featuring a world-renowned faculty, DFCon 09 provides the opportunity to review state-of-the-art concepts and techniques. For more information on DFCon 09, visit www.DFCon.com.

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc. (OTC Bulletin Board:WNDM), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company please visit the Company's Website at www.Celleraterx.com.

"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

    For more information, contact:
    Product Information
    Cathy Bradshaw
    President
    954-315-9242

    Shareholder Relations
    Lucy Singleton
    Secretary
    817-820-7080


'/>"/>
SOURCE Wound Management Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arobella Medical Announces European CE Mark Approval of Qoustic Wound Therapy System(TM)
2. The American Legion Strongly Opposed to Presidents Plan to Charge Wounded Heroes for Treatment
3. Wound Be Gone: Quickly Gaining Strong Support from Clinician Experts in the Field of Wound Healing
4. Wound Management Technologies Joins IMCO Vendor Network to Expand Sales Nationwide
5. Association for the Advancement of Wound Care (AAWC) Leads Pressure Ulcer Care Initiative
6. ConvaTec Announces Divestiture of Unomedical Wound Care and Ophthalmics Business
7. Wound Care Certification Course Endorsed by the American College of Certified Wound Specialists
8. Smith & Nephew Announce the New RENASYS EZ(TM) System for Negative Pressure Wound Therapy
9. Wounded Warrior Projects Project Odyssey Aims to Teach Coping Skills for Combating Post-Traumatic Stress in Wounded Warriors
10. Advanced Wound Technologies Mid-Atlantic, Inc. Announces Name Change and Reverse Stock Split
11. Regional Anesthesia Eases Wounded Soldiers Pain in Iraq and Afghanistan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... ... prolapse with the latest techniques and the most minimally invasive approaches. , Women ... prolapse, particularly after menopause. Other risk factors include surgery to the pelvic floor, ...
(Date:2/7/2016)... , ... February 07, 2016 , ... ... program. MyDecision™ empowers employers and organizations with the tools and information to lower ... three elements to cut the cost of providing employee healthcare benefits by as ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT: ... world with an estimated 5000 perioperative nurses in attendance to study the ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX ... warm color grades to their footage. A LUT is a Lookup Table that contains ... the corresponding color indicated by the table. By manipulating each pixel, LUT's can change ...
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Syneron Medical Ltd. (NASDAQ: ELOS ... today that William Griffing , Chief Executive ... to participate in the Leerink Partners 5 th ... 2016 in New York City ... meet with the Mr. Griffing and will include ...
(Date:2/5/2016)... Feb. 5, 2016  As people age, it is ... of recommended screenings and tests that are linked with ... However, for the majority of aging individuals, hearing health ... For the 37.5 million American adults who report some ... to make hearing health a 2016 healthy aging priority.[1] ...
(Date:2/5/2016)...  Aralez Pharmaceuticals Inc. ("Aralez") today announced the completion ... Pharmaceuticals Canada Inc. ("Tribute") following approval of the transaction ... combined company will operate under Aralez Pharmaceuticals Inc. ("Aralez"), ... Canada , Ireland ... the terms of the Agreement and Plan of Merger ...
Breaking Medicine Technology: